98 related articles for article (PubMed ID: 11925140)
1. The significance of serum CA 125 elevation in malignant and nonmalignant diseases.
Sjövall K; Nilsson B; Einhorn N
Gynecol Oncol; 2002 Apr; 85(1):175-8. PubMed ID: 11925140
[TBL] [Abstract][Full Text] [Related]
2. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
[TBL] [Abstract][Full Text] [Related]
3. Serum CA-125 measurements > 65 U/mL. Clinical value.
Eltabbakh GH; Belinson JL; Kennedy AW; Gupta M; Webster K; Blumenson LE
J Reprod Med; 1997 Oct; 42(10):617-24. PubMed ID: 9350014
[TBL] [Abstract][Full Text] [Related]
4. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
5. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer.
Vuento MH; Stenman UH; Pirhonen JP; Mäkinen JI; Laippala PJ; Salmi TA
Gynecol Oncol; 1997 Jan; 64(1):141-6. PubMed ID: 8995563
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of the Stockholm screening study on ovarian cancer.
Einhorn N; Bast R; Knapp R; Nilsson B; Zurawski V; Sjövall K
Gynecol Oncol; 2000 Dec; 79(3):466-70. PubMed ID: 11104621
[TBL] [Abstract][Full Text] [Related]
7. Increased mortality in postmenopausal women with serum CA125 elevation.
Jeyarajah AR; Ind TE; MacDonald N; Skates S; Oram DH; Jacobs IJ
Gynecol Oncol; 1999 May; 73(2):242-6. PubMed ID: 10329041
[TBL] [Abstract][Full Text] [Related]
8. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
[TBL] [Abstract][Full Text] [Related]
9. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
[TBL] [Abstract][Full Text] [Related]
10. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Markman M; Federico M; Liu PY; Hannigan E; Alberts D
Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
[TBL] [Abstract][Full Text] [Related]
11. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer risk factors and second primary malignancies among women with breast cancer.
Trentham-Dietz A; Newcomb PA; Nichols HB; Hampton JM
Breast Cancer Res Treat; 2007 Oct; 105(2):195-207. PubMed ID: 17186360
[TBL] [Abstract][Full Text] [Related]
13. CA 125 as an indicator of pleural metastases in breast cancer patients.
Krämer S; Raff U; Jäger W; Lang N
Anticancer Res; 1996; 16(5B):3165-8. PubMed ID: 8920785
[TBL] [Abstract][Full Text] [Related]
14. CA 125 is an indicator for pleural metastases in breast cancer.
Krämer S; Jäger W; Lang N
Anticancer Res; 1997; 17(4B):2967-70. PubMed ID: 9329577
[TBL] [Abstract][Full Text] [Related]
15. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.
Santillan A; Garg R; Zahurak ML; Gardner GJ; Giuntoli RL; Armstrong DK; Bristow RE
J Clin Oncol; 2005 Dec; 23(36):9338-43. PubMed ID: 16361633
[TBL] [Abstract][Full Text] [Related]
16. Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125.
Allen GW; Forouzannia A; Bailey HH; Howard SP
Gynecol Oncol; 2004 Sep; 94(3):811-3. PubMed ID: 15350377
[TBL] [Abstract][Full Text] [Related]
17. Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer.
Skírnisdóttir I; Garmo H; Holmberg L
Gynecol Oncol; 2007 Apr; 105(1):166-71. PubMed ID: 17184826
[TBL] [Abstract][Full Text] [Related]
18. Primary malignancy after primary female breast cancer in the South of the Netherlands, 1972-2001.
Soerjomataram I; Louwman WJ; de Vries E; Lemmens VE; Klokman WJ; Coebergh JW
Breast Cancer Res Treat; 2005 Sep; 93(1):91-5. PubMed ID: 16184464
[TBL] [Abstract][Full Text] [Related]
19. The risk of cancer and the role of parity among women with endometriosis.
Melin A; Sparén P; Bergqvist A
Hum Reprod; 2007 Nov; 22(11):3021-6. PubMed ID: 17855408
[TBL] [Abstract][Full Text] [Related]
20. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
